Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Scientists document a death from a meat allergy tied to certain ticks - 2Doctors thought he had cancer. An offhand suggestion led to a rare diagnosis.
- 3'Crammed into a cell with vermin at New Year'
- 4I was about to film a movie with Glen Powell when my hair started falling out in clumps. Alopecia has made me unrecognizable as an actor.
- 5Virtual reality opens doors for older people to build closer connections in real life
- Volcanic eruption led to the Black Death, new research suggests
- Second doctor in Matthew Perry overdose case sentenced to home confinement
- When darkness shines: How dark stars could illuminate the early universe
- Yemen’s Aden airport shut by STC-backed transport minister, Saudi source says
- In blow to Lula, Brazil Congress revives controversial environmental bill
- Obamacare enrollment declines as US subsidies expire
- 'Supergirl' drops 1st teaser trailer: Watch Milly Alcock as Kara Zor-El and the return of Krypto the Superdog
- Figure out How to Plan for Your Web-based Degree monetarily
- The 15 Most Powerful Forerunners in Business
